TTM
$28.91B
YoY change
+65.7%
5Y CAGR
+11.4%
Peak year (2025)
$41.05B
Cumulative EBITDA
$595.00B
EBITDA history chart for Johnson & Johnson (JNJ) from 1985 to 2025
Latest: $41.05B
EBITDA growth chart for Johnson & Johnson (JNJ) from 1985 to 2025
Latest: +65.7%
EBITDA history table for Johnson & Johnson (JNJ) from 1985 to 2025
| 2025 | $41.05B | +65.7% | +$16.27B | ||
| 2024 | $24.78B | +6.3% | +$1.46B | ||
| 2023 | $23.32B | -12.3% | −$3.29B | ||
| 2022 | $26.61B | -0.5% | −$146.00M | ||
| 2021 | $26.75B | +11.8% | +$2.82B | ||
| 2020 | $23.93B | -2.9% | −$726.00M | ||
| 2019 | $24.66B | -4.9% | −$1.28B | ||
| 2018 | $25.93B | +6.9% | +$1.68B | ||
| 2017 | $24.25B | -0.1% | −$34.00M | ||
| 2016 | $24.28B | +3.4% | +$789.00M | ||
| 2015 | $23.49B | -6.0% | −$1.50B | ||
| 2014 | $24.99B | +24.6% | +$4.93B | ||
| 2013 | $20.06B | +11.6% | +$2.08B | ||
| 2012 | $17.97B | +11.7% | +$1.88B | ||
| 2011 | $16.09B | -20.9% | −$4.25B | ||
| 2010 | $20.34B | +7.2% | +$1.36B | ||
| 2009 | $18.98B | -6.0% | −$1.22B | ||
| 2008 | $20.20B | +23.5% | +$3.84B | ||
| 2007 | $16.36B | +3.0% | +$470.00M | ||
| 2006 | $15.89B | +6.4% | +$962.00M | ||
| 2005 | $14.92B | +3.1% | +$444.00M | ||
| 2004 | $14.48B | +13.7% | +$1.74B | ||
| 2003 | $12.74B | +12.3% | +$1.40B | ||
| 2002 | $11.34B | +19.5% | +$1.85B | ||
| 2001 | $9.49B | +15.6% | +$1.28B | ||
| 2000 | $8.21B | +9.5% | +$712.00M | ||
| 1999 | $7.50B | +18.7% | +$1.18B | ||
| 1998 | $6.31B | +11.0% | +$624.00M | ||
| 1997 | $5.69B | +7.1% | +$377.00M | ||
| 1996 | $5.31B | +21.6% | +$944.00M | ||
| 1995 | $4.37B | +23.7% | +$837.00M | ||
| 1994 | $3.53B | +17.3% | +$520.00M | ||
| 1993 | $3.01B | +6.1% | +$174.00M | ||
| 1992 | $2.84B | +6.8% | +$180.00M | ||
| 1991 | $2.66B | +7.7% | +$191.00M | ||
| 1990 | $2.47B | +18.8% | +$391.00M | ||
| 1989 | $2.08B | +15.6% | +$280.00M | ||
| 1988 | $1.79B | +14.7% | +$230.00M | ||
| 1987 | $1.56B | +24.3% | +$306.20M | ||
| 1986 | $1.26B | +15.4% | +$168.30M | ||
| 1985 | $1.09B | — | — |
- 2025$41.05B+65.7%
- 2024$24.78B+6.3%
- 2023$23.32B-12.3%
- 2022$26.61B-0.5%
- 2021$26.75B+11.8%
- 2020$23.93B-2.9%
- 2019$24.66B-4.9%
- 2018$25.93B+6.9%
- 2017$24.25B-0.1%
- 2016$24.28B+3.4%
- 2015$23.49B-6.0%
- 2014$24.99B+24.6%
- 2013$20.06B+11.6%
- 2012$17.97B+11.7%
- 2011$16.09B-20.9%
- 2010$20.34B+7.2%
- 2009$18.98B-6.0%
- 2008$20.20B+23.5%
- 2007$16.36B+3.0%
- 2006$15.89B+6.4%
- 2005$14.92B+3.1%
- 2004$14.48B+13.7%
- 2003$12.74B+12.3%
- 2002$11.34B+19.5%
- 2001$9.49B+15.6%
- 2000$8.21B+9.5%
- 1999$7.50B+18.7%
- 1998$6.31B+11.0%
- 1997$5.69B+7.1%
- 1996$5.31B+21.6%
- 1995$4.37B+23.7%
- 1994$3.53B+17.3%
- 1993$3.01B+6.1%
- 1992$2.84B+6.8%
- 1991$2.66B+7.7%
- 1990$2.47B+18.8%
- 1989$2.08B+15.6%
- 1988$1.79B+14.7%
- 1987$1.56B+24.3%
- 1986$1.26B+15.4%
- 1985$1.09B—
EBITDA values are taken from Johnson & Johnson's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About EBITDA at Johnson & Johnson (JNJ)
According to Johnson & Johnson's latest reported financial statements, the company's current EBITDA (TTM) is $28.91B. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a common proxy for operating cash generation that strips out non-cash charges (depreciation and amortization) and capital structure effects (interest, taxes). Useful for comparing companies with different leverage and asset bases — see operating income and net income for fully GAAP figures.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
As of the 2025 fiscal year, Johnson & Johnson (JNJ) reported EBITDA of $41.05B – surged 65.7% year-over-year.
Johnson & Johnson EBITDA has grown for 2 consecutive years, with a +11.4% compound annual growth rate over 2020–2025 (5 years).
Across the available history, EBITDA reached its high of $41.05B in 2025 and its low of $1.09B in 1985.
Johnson & Johnson EBITDA by Year
Johnson & Johnson EBITDA 2025: $41.05B
Johnson & Johnson posted EBITDA of $41.05B in 2025, surged 65.7% from 2024. This figure represents the highest annual value in the available history.
Johnson & Johnson EBITDA 2024: $24.78B
In 2024, Johnson & Johnson reported EBITDA of $24.78B, grew 6.3% from 2023.
Johnson & Johnson EBITDA 2023: $23.32B
Johnson & Johnson EBITDA in 2023 was $23.32B, declined 12.3% below 2022.
Johnson & Johnson EBITDA 2022: $26.61B
2022's EBITDA for Johnson & Johnson came in at $26.61B, edged down 0.5% below 2021.
Johnson & Johnson EBITDA 2021: $26.75B
Johnson & Johnson EBITDA in 2021 was $26.75B.
See more financial history for Johnson & Johnson (JNJ).
Sector peers by EBITDA
Healthcare peers of Johnson & Johnson (JNJ), ranked by their latest EBITDA
| $28.26B | |
| $27.94B | |
| $24.43B | |
| $23.06B | |
| $19.83B | |
| $17.63B | |
| $16.90B | |
| $11.47B |
- $28.26B
- $27.94B
- $24.43B
- $23.06B
- $19.83B
- $17.63B
- $16.90B
Frequently asked questions
Johnson & Johnson (JNJ) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation